Trump presidency could prove a salve for pharma merger deals

NEW YORK, Nov 11 (Reuters) - Biotechnology companies, whose

U.S. shares soared Wednesday after Republican Donald Trump's

presidential election, may soon see another benefit: an uptick

in biotech M&A.

Read more